Ideas For Now-

STC-->

SITE-->

BNTX-->

INO-->

ZYME-->

ABUS--> Up 10% yesterday and another 12.6% this morning. At one point they ran up because of a court situation in which they may make money ultimately off one of these vaccines I think MDRNA's...That all settled and this is about Heb B -But with that maybe kicker.....
I did not comprehend the press release...

Ok this is getting interesting. Hold up. This was the news on 8/11

Arbutus Biopharma higher after Moderna discusses patent uncertainty 08/11 ABUS, MRNA Moderna (MRNA) said in a regulatory filing that the company "cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273." Previously, on July 24, Moderna released a statement that read in part: "The recently issued Patent Trial and Appeal Board ruling on the 8,058,069 patent relates to Moderna's challenge to certain legacy patents held by Arbutus (ABUS), commenced well before the development of mRNA-1273. These actions were taken by Moderna in response to the longstanding aggressive posture taken by Arbutus and its predecessor company against many developers of nucleic acid-based therapeutics." In early afternoon trading, Arbutus shares are up 17c, or 4.6%, to $3.83.

Was $3.83 Now $2.62 before the open..... You know what.... This could be good...
 
on Aug 27 B Riley said this)

Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR 07/27 ABUS B. Riley FBR analyst Mayank Mamtani raised the firm's price target on Arbutus Biopharma to $8 from $6 and keeps a Buy rating on the shares following a virtual meeting with management. The company is actively contributing data from internal viral libraries to the COVID-19 R&D consortium, a joint effort of pharmaceutical and biotech companies pooling resources and coordinating screening and active compound validation efforts to try to accelerate the development process, Mamtani tells investors in a research note. Further, Arbutus remains on track to report incremental data from the Phase I dose escalation study of AB-729 to provide clarity on the clinical and regulatory path forward in hepatitis B virus in Q4, adds the analyst.

Q4?

That news came out today. $8 target $3.00 stock.
 
This is interesting-- Insider buys first ever shares--- about a month ago.

Harpoon Therapeutics Inc (NASDAQ:HARP) was trading 5.5% higher from the previous closing price. Erbez Georgia filed a Form 4 with the SEC on Tuesday, August 4. The insider bought 1,817 shares at an average price of $10.92. After the transaction, the executive's stake in Harpoon Therapeutics Inc. moved to 1,817 shares.

Nice timing. stk is $17-! Surely a coincidence.
 
stonedinvestor said:
The difference between me and a straight service that may list reams and reams of info on vol alerts and such is-- I know the companies. Just like NGM (in IFN portfolio) I followed BCYC all through their IPO and did a lot of research so I know that they are going to absolutly change everything- though I half forget why-- and have a very smart group of people behind them. Or so I thought the IPO languished a year until now. Why did it move yesterday?

That's to be seen... Could good news be coming.
More...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc , a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT8009 will be presented during an e-poster session at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on September 19-21, 2020. BT8009 is a second-generation Bicycle Toxin Conjugate (BTC), which uses a valine-citrulline cleavable linker and a cytotoxin MMAE payload. BT8009 targets Nectin-4, a tumor antigen observed to be overexpressed in several common tumor types and associated with poor disease prognosis.

“We believe BT8009 represents an important addition to the landscape of potential next-generation treatments for patients with Nectin-4-positive cancers, as it could improve on Nectin-4-targeted therapies that are based on conventional modalities,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics(BCYC). “With our recent announcement that the first patient has been dosed in the Phase I/II trial of BT8009, we are pleased that the trial is progressing and look forward to providing an overview of its design at ESMO.”

Details on Bicycle’s poster presentation at ESMO are as follows:

Poster Title: BT8009-100 Phase I/II Study of the Safety, Pharmacokinetics, & Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies
Abstract #: 3716
Presentation #: 599TiP

The poster will be available on the ESMO website, as well as in the Publications section of bicycletherapeutics.com, beginning Thursday, September 17.

About Bicycle Therapeutics(BCYC)
Bicycle Therapeutics (BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.
 
stonedinvestor said:
This is interesting-- Insider buys first ever shares--- about a month ago.

Harpoon Therapeutics Inc (NASDAQ:HARP) was trading 5.5% higher from the previous closing price. Erbez Georgia filed a Form 4 with the SEC on Tuesday, August 4. The insider bought 1,817 shares at an average price of $10.92. After the transaction, the executive's stake in Harpoon Therapeutics Inc. moved to 1,817 shares.

Nice timing. stk is $17-! Surely a coincidence.
More...
He bought a total of 7000 more on 8/18 and 8/19 for 11.60 /11.40
 
Inside Info ? Sketchy when they go from zero shares to suddenly buying....

INO is still moving Motlet Fools did this-) They were part of 3 Virus stks that could double-


3. Inovio
Inovio Pharmaceuticals' (NASDAQ:INO) shares have risen close to 240% so far in 2020. By late June, the stock was up by nearly 850%. However, Inovio gave up much of its big gain after announcing interim phase 1 results for its COVID-19 vaccine candidate, INO-4800.

Those results weren't bad. In fact, Inovio reported that 94% of the phase 1 study participants demonstrated overall immune responses after two doses of INO-4800. The investigational vaccine also appeared to be well-tolerated, with no serious adverse events. The problem was that industry observers wanted more details about immune responses than Inovio provided.

Don't count Inovio out, though. The biotech has submitted a paper detailing its phase 1 results for peer review and expects publication in the coming weeks. Inovio awaits FDA clearance to begin phase 2/3 trials in the U.S., which it anticipates receiving in the near future. CEO Joseph Kim also recently stated that the company is "very confident" it will be able to line up external funding for its phase 2/3 studies.

I'm a little nervous.....
 
Arbutus Biopharma Corporation (ABUS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD

2.96+0.34 (+12.9771%)<----- Lets watch frsiky vol....
As of 9:56AM EDT. Market open.
 
Reason--

- Stock off high of day with HUGE volume.
-So people are watching probably because of the patent connection with Moderna
- I love threads that have ideas that we comeback to and we already went through the lottery type ticket this stock was as MDRNA advances a settlement perhaps? I would think so, any patent trial would delay things.. maybe the Gov would step in..That's apossibilitythey could also force a settlement BUT now we have this 2nd reason as well...

I read through the data this am and honestly it was dense. I am really good at this stuff and I didn't understand a whit but luckily someone else did:

Arbutus HBV data 'could represent a turning point,' says Chardan 12:12 ABUS Arbutus Biopharma this morning announced "impressive" interim data from the Phase Ia/Ib clinical trial evaluating its lead asset, AB-729, as a treatment for chronic hepatitis B virus, Chardan analyst Keay Nakae tells investors in a research note. The data show an even greater knockdown of HBsAg compared to what was observed at 12 weeks for a single 60 mg dose, says the analyst. Nakae believes the positive results for AB-729 "could represent a turning point" for Arbutus and lead to a partnership. The analyst maintains a Buy rating on the shares with a $5 price target.
 
You must log in or register to reply here.
Back
Top